(Q35194386)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Terry A Jacobson

series ordinal

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

269-286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Drug-induced rhabdomyolysis--mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Comparative tolerability of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Drug-induced myopathies in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

The human drug metabolizing cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

The myotoxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Clofibrate-lnduced acute muscular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Cyclosporin A hepatotoxicity in 66 renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Physiological disposition of HMG-CoA-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Efficacy and long-term adverse effect pattern of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

The use of statins after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.269

21 January 2018

Identifiers

DOI

10.1517/14740338.2.3.269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904106%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference